LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)
Titel:
LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)
Auteur:
Dong, J. Han, G. Ogasawara, S. Liu, R. Gu, S. Liu, F. Zhao, M. Hu, H. Liu, Z. Lin, K. Liu, J. Lin, Z. Zhang, Y. Peng, T. Song, J. Ueno, M. Zhu, J. Bai, L. Shi, Y. Kudo, M.